Avtor/Urednik		Takač, Iztok
Naslov		Hormonsko nadomestno zdravljenje v peri- in pomenopavzi
Prevedeni naslov		Hormone replacement therapy in peri- and postmenopause
Tip		članek
Vir		In: Hojs R, Krajnc I, Pahor A, et al, editors. Iz prakse za prakso. Zbornik predavanj in praktikum 16. srečanje internistov in zdravnikov splošne medicine z mednarodno udeležbo; 2005 maj 20-21; Maribor. Maribor: Splošna bolnišnica Maribor,
Leto izdaje		2005
Obseg		str. 91-105
Jezik		slo
Abstrakt		Recommendations for medical practitioners on the appropriate use of estrogen and progestogen therapy in peri- and postmenopause are provided. The majority of middle-aged women experience menopausal symptoms that are a direct consequence of a decrease in estrogen levels and are also a most frequent indication for hormone replacement therapy (HRT). HRT is indicated in urogenital atrophy, for prevention and treatment of osteoporosis and ir premature menopause (before age 40). In HRT the dose of estrogen should be the lowest needed to relieve symptoms and the duration of treatment is based on the indication. Before HRT pretreatment assessment is necessary and during treatment patients should be reevaluated annually. Long-term HRT involves some additional risk of breast cancer, venous and pulmonar thromboembolic disease, gallbladder stones and endometrial cancer. Befor starting HRT, the contraindications for this treatment should be evaluated. In such cases alternative therapies can be considered.
Deskriptorji		ESTROGEN REPLACEMENT THERAPY OSTEOPOROSIS POSTMENOPAUSE MENOPAUSE BREAST NEOPLASMS THROMBOEMBOLISM